Publication | Open Access

Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression

Hematological MalignancyBone Marrow FailureMyelodysplastic Syndromes PatientsMedicineHematologyImmunologyPathologyArsenic TrioxideThalidomide CombinationAplastic AnemiaMyeloid Neoplasia